Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Short term Debt (2016 - 2023)

Arcadia Biosciences filings provide 10 years of Short term Debt readings, the most recent being $15000.0 for Q1 2023.

  • On a quarterly basis, Short term Debt fell 78.26% to $15000.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $15000.0, a 78.26% decrease, with the full-year FY2022 number at $48000.0, down 25.0% from a year prior.
  • Short term Debt hit $15000.0 in Q1 2023 for Arcadia Biosciences, down from $48000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.1 million in Q1 2021 to a low of $12000.0 in Q1 2019.
  • Median Short term Debt over the past 5 years was $48000.0 (2022), compared with a mean of $200058.8.
  • Biggest five-year swings in Short term Debt: surged 7031.25% in 2021 and later crashed 93.95% in 2022.
  • Arcadia Biosciences' Short term Debt stood at $40000.0 in 2019, then skyrocketed by 100.0% to $80000.0 in 2020, then decreased by 20.0% to $64000.0 in 2021, then fell by 25.0% to $48000.0 in 2022, then tumbled by 68.75% to $15000.0 in 2023.
  • The last three reported values for Short term Debt were $15000.0 (Q1 2023), $48000.0 (Q4 2022), and $47000.0 (Q3 2022) per Business Quant data.